BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15017238)

  • 1. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.
    Tanvetyanon T; Choudhury AM
    J Urol; 2004 Apr; 171(4):1627. PubMed ID: 15017238
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
    Patel H; Rhee E; Zimmern PE
    J Urol (Paris); 1996; 102(3):123-5. PubMed ID: 9091557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fulminant liver failure with a fatal outcome due to flutamide].
    Fernández Peña CM; Morano Amado LE; Montes Santiago J; Fachal C
    Med Clin (Barc); 1997 Feb; 108(6):237-8. PubMed ID: 9102495
    [No Abstract]   [Full Text] [Related]  

  • 4. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
    Lin CJ; Hsieh RK; Lim KH; Chen HH; Cheng YC; Wu CJ
    South Med J; 2007 Sep; 100(9):916-7. PubMed ID: 17902299
    [No Abstract]   [Full Text] [Related]  

  • 5. Bicalutamide-associated fulminant hepatic failure.
    Chodak GW
    Urology; 1997 Dec; 50(6):1027. PubMed ID: 9426744
    [No Abstract]   [Full Text] [Related]  

  • 6. Fulminant liver failure associated with flutamide therapy for hirsutism.
    Andrade RJ; Lucena MI; Fernández MC; Suárez F; Montero JL; Fraga E; Hidalgo F
    Lancet; 1999 Mar; 353(9157):983. PubMed ID: 10459914
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fatal fulminating hepatitis caused by nilutamide. A new case].
    Marty F; Godart D; Doermann F; Mérillon H
    Gastroenterol Clin Biol; 1996; 20(8-9):710-1. PubMed ID: 8977826
    [No Abstract]   [Full Text] [Related]  

  • 8. [Fulminant liver failure induced by flutamide].
    Rodríguez Gómez SJ; Martínez Moreno J; Martín Arribas MI; Pérez Villoria A; De la Serna Higuera C; Betancourt González A
    Rev Esp Enferm Dig; 2000 Jun; 92(6):411. PubMed ID: 10985104
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fulminant hepatitis associated with treatment with flutamide].
    García-Gascó P; Morata Aldea C; Segura Huertas A; Aparicio Urtasun J
    Med Clin (Barc); 1997 Dec; 109(20):820. PubMed ID: 9493166
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    Whelan P
    Eur Urol; 2008 Oct; 54(4):823-4. PubMed ID: 18243509
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular implications of the antiandrogen withdrawal syndrome.
    Moul JW; Srivastava S; McLeod DG
    Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulminant hepatic failure associated with bicalutamide.
    Schellhammer PF
    Urology; 1997 Nov; 50(5):827. PubMed ID: 9372905
    [No Abstract]   [Full Text] [Related]  

  • 14. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 16. [A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer].
    Satoh T; Egawa S; Katsuta M; Iwamura M; Uchida T; Koshiba K
    Nihon Hinyokika Gakkai Zasshi; 1997 Jul; 88(7):694-6. PubMed ID: 9267134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal fulminant hepatic failure due to cyproterone acetate.
    Friedman G; Lamoureux E; Sherker AH
    Dig Dis Sci; 1999 Jul; 44(7):1362-3. PubMed ID: 10489919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe acute hepatitis due to flutamide and elevated CA 19.9].
    Ramírez R; Ruiz MA; Auguet T; Richart C
    Gastroenterol Hepatol; 2005; 28(7):433. PubMed ID: 16137480
    [No Abstract]   [Full Text] [Related]  

  • 20. Is photopatch testing useful in the investigation of photosensitivity due to flutamide?
    Martín-Lázaro J; Buján JG; Arrondo AP; Lozano JR; Galindo EC; Capdevila EF
    Contact Dermatitis; 2004 May; 50(5):325-6. PubMed ID: 15209825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.